# VACCINE/PROPHYLACTIC TRIAL SUMMARY

###### Bold = Included or in process of being included in COVID Trial Dash map
###### Companies listed chronological according to P3 trial start. Trials listed chronologically.

---
**University of Oxford &amp; AstraZeneca** - AZD1222; ChAdOx1 nCoV-19
- [Phase 1/2](https://clinicaltrials.gov/ct2/show/NCT04324606) - 1,090 subjects - Started April 23 2020 - [Results](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)31604-4/fulltext)
- [Phase 1/2](https://clinicaltrials.gov/ct2/show/NCT04444674) - 2,130 subjects - Started June 24 2020
- [Phase 2/3](https://clinicaltrials.gov/ct2/show/NCT04400838) - 12,390 subjects (UK) - Started May 28 2020
- [Phase 3](https://www.clinicaltrials.gov/ct2/show/NCT04536051) - 10,300 subjects (Brazil) - Started June 2 2020
- [Phase 3](https://www.clinicaltrials.gov/ct2/show/NCT04444674) - 2,130 subjects (South Africa) - Started June 24 2020
- [Phase 1/2](https://www.clinicaltrials.gov/ct2/show/NCT04568031) - 256 subjects (Japan) - Started August 23 2020
- [Phase 3](https://www.clinicaltrials.gov/ct2/show/NCT04516746) - 30,000 subjects (US) - Started August 28 2020
- [Phase 3](https://www.clinicaltrials.gov/ct2/show/NCT04540393) - 100 subjects (Russia) - Started September 2 2020 - Suspended
- [Phase 2](https://clinicaltrials.gov/ct2/show/NCT04686773) - 100 subjects (Azerbaijan) - Started February 10 2021
- [Phase 1/2](https://clinicaltrials.gov/ct2/show/NCT04684446) - 100 subjects (Russia) - Starting March 16 2021

**Sinopharm &amp; Beijing Institute of Biological Products** - Inactivated Vaccine
- [Preclinical Results](https://www.cell.com/cell/pdf/S0092-8674(20)30695-4.pdf)
- [Phase 1/2](http://www.chictr.org.cn/showproj.aspx?proj=53003) - 2048 subjects (China) - Started April 28 2020
- [Phase 3](https://clinicaltrials.gov/ct2/show/NCT04510207) - 45,000 subjects (Bahrain, Egypt, Jordan, UAE) - Started July 16 2020
- [Phase 3](https://clinicaltrials.gov/ct2/show/NCT04560881?term=NCT04560881&amp;draw=2&amp;rank=1) - 3,000 subjects (Argentina) - Started September 16 2020

**Sinovac** - CoronaVac
- [Phase 1/2](https://clinicaltrials.gov/ct2/show/NCT04352608) - 744 subjects (144 Phase 1 / 600 Phase 2) - Started April 16 2020 - [Interim Results](https://www.statnews.com/2020/06/14/sinovac-early-data-covid19-vaccine-generated-immune-responses/)
- [Phase 1/2](https://clinicaltrials.gov/ct2/show/NCT04383574) - 422 subjects - Started May 22 2020
- [Phase 1/2](https://www.clinicaltrials.gov/ct2/show/NCT04551547) - 552 subjects - Started October 31 2020
- [Phase 3](https://clinicaltrials.gov/ct2/show/NCT04456595) - 13,060 subjects (healthcare professionals; Brazil) - Started July 21 2020
- [Phase 3](https://www.clinicaltrials.gov/ct2/show/NCT04508075) - 1,620 subjects (Indonesia) - Started August 10 2020
- [Phase 3](https://www.clinicaltrials.gov/ct2/show/NCT04582344) - 13,000 subjects (Turkey) - Started September 14 2020
- [Phase 3](https://clinicaltrials.gov/ct2/show/NCT04617483) - 1,040 subjects (China) - Started October 31 2020
- [Phase 3](https://clinicaltrials.gov/ct2/show/NCT04651790) - 2,300 subjects (Chile) - Started November 27 2020

**Moderna Therapeutics** - mRNA-1273
- [Phase 1](https://www.clinicaltrials.gov/ct2/show/NCT04283461) - 120 subjects - Started March 16 2020 - [Interim Results](https://www.nejm.org/doi/full/10.1056/NEJMoa2022483)
- [Phase 2](https://www.clinicaltrials.gov/ct2/show/NCT04405076) - 600 subjects (US) - Started May 29 2020
- [Phase 3](https://clinicaltrials.gov/ct2/show/NCT04470427?term=NCT04470427) - 30,000 subjects (US) - Started July 27 2020
- [Phase 2/3](https://clinicaltrials.gov/ct2/show/NCT04649151) - 3,000 _adolescent_ subjects (US) - Started December 9 2020

**BioNTech &amp; Pfizer** - BNT162
- [Phase 1/2](https://www.clinicaltrials.gov/ct2/show/NCT04380701) - 456 subjects - Started April 23 2020 - [Interim Results](https://www.medrxiv.org/content/10.1101/2020.06.30.20142570v1)[Results](https://www.medrxiv.org/content/10.1101/2020.07.17.20140533v1)
- [Phase 2/3](https://clinicaltrials.gov/ct2/show/NCT04368728) - 43,998 subjects (US) - Started April 29, 2020 (P3 July 27) - [Interim Results](https://investors.pfizer.com/investor-news/press-release-details/2020/Pfizer-and-BioNTech-Announce-Vaccine-Candidate-Against-COVID-19-Achieved-Success-in-First-Interim-Analysis-from-Phase-3-Study/default.aspx)
- [Phase 1](https://www.clinicaltrials.gov/ct2/show/NCT04523571) - 144 subjects (China) - Started July 28 2020
- [Phase 1/2](https://www.clinicaltrials.gov/ct2/show/NCT04537949) - 120 subjects (Germany) - Started September 9 2020
- [Phase 1/2](https://www.clinicaltrials.gov/ct2/show/NCT04588480) - 160 subjects (Japan) - Started October 21, 2020
- [Phase 2](https://www.clinicaltrials.gov/ct2/show/NCT04649021) - 960 subjects (China) - Started December 4 2020
- [Phase 3](https://clinicaltrials.gov/ct2/show/NCT04713553) - 1,280 subjects - Started January 28, 2021

**CanSino Biologics** - Ad5-nCoV
- [Phase 1](https://www.clinicaltrials.gov/ct2/show/NCT04313127) - 108 subjects - started March 16 2020 - [Results](https://www.thelancet.com/pdfs/journals/lancet/PIIS0140-6736(20)31208-3.pdf)
- [Phase 2](https://www.clinicaltrials.gov/ct2/show/NCT04341389) - 508 subjects - Started April 12 2020 - [Results](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)31605-6/fulltext)
- [Phase 3](https://www.clinicaltrialsarena.com/news/cansino-vaccine-saudi-trial/) - 5,000 subjects (Saudi Arabia) - Status Uncertain
- [Phase 1/2](https://clinicaltrials.gov/ct2/show/NCT04398147) - 696 subjects (Canada) - Starting August 1 2020
- [Phase 3](https://www.clinicaltrials.gov/ct2/show/NCT04540419) - 500 subjects (Russia) - Started September 11 2020
- [Phase 3](https://www.clinicaltrials.gov/ct2/show/NCT04526990) - 40,000 subjects - Started August 2020
- [Phase 2](https://www.clinicaltrials.gov/ct2/show/NCT04566770) - 481 subjects (China) - Started September 24, 2020
- [Phase 1](https://clinicaltrials.gov/ct2/show/NCT04552366) - 149 subjects (China) - Started September 29 2020

**Johnson &amp; Johnson / Janssen** - Ad26.COV2-S
- [Phase 1](https://clinicaltrials.gov/ct2/show/NCT04509947) - 250 subjects - Started August 11 2020
- [Phase 1/2](https://www.clinicaltrials.gov/ct2/show/NCT04436276) - 1,045 subjects - Started July 15 2020
- [Phase 3](https://clinicaltrials.gov/ct2/show/NCT04505722) - 44,325 subjects (Single Dose) - Started September 7 2020
- [Phase 3](https://www.clinicaltrials.gov/ct2/show/NCT04614948) - 30,000 subjects (Double Dose) - Started November 15 2020

**Gamaleya Research Institute** - Gam-COVID-Vac
- [Phase 1/2](https://clinicaltrials.gov/ct2/show/NCT04436471) - 38 subjects (Russia) - Started June 17 2020
- [Phase 1/2](https://clinicaltrials.gov/ct2/show/NCT04437875) - 38 subjects (Russia) - Started June 17 2020
- [Phase 3](https://clinicaltrials.gov/ct2/show/NCT04530396) - 33,758 subjects (Russia) - Started September 7 2020 - [Interim Results](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)00234-8/fulltext)
- [Phase 3](https://clinicaltrials.gov/ct2/show/NCT04564716) - 100 subjects (Belarus) - Started September 28 2020
- [Phase 2](https://clinicaltrials.gov/ct2/show/NCT04587219) - 110 subjects (Russia) - Started October 22 2020
- [Phase 3](https://clinicaltrials.gov/ct2/show/NCT04642339) - 2,000 subjects (Venezuela) - November 2020
- [Phase 3](https://clinicaltrials.gov/ct2/show/NCT04656613) - 1,000 subjects (UAE) - Started December 2020
- [Phase 2/3](http://ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=49102&amp;EncHid=&amp;userName=Sputnik) - 1,600 subjects (India) - Started December 1 2020

**Sinopharm &amp; Wuhan Institute of Biological Products** - Inactivated Vaccine
- [Phase 1/2](https://www.fiercepharma.com/pharma-asia/china-s-sinopharm-touts-100-antibody-response-for-covid-19-vaccine-it-s-already-giving) - 1,120 subjects - Started April 12 2020 - - [Results](https://www.fiercepharma.com/pharma-asia/china-s-sinopharm-touts-100-antibody-response-for-covid-19-vaccine-it-s-already-giving)
- [Phase 3](https://clinicaltrials.gov/ct2/show/NCT04612972) - [12,000](https://www.nytimes.com/live/2020/12/16/world/covid-19-coronavirus#the-clinical-trials-of-a-chinese-vaccine-resume-in-peru-after-a-volunteers-illness-is-deemed-unrelated) subjects (Peru) - Started September 10 2020

**Novavax** - NVXâ€‘CoV2373
- [Preclinical Results](https://www.biorxiv.org/content/10.1101/2020.06.29.178509v1)
- [Phase 1/2](https://www.clinicaltrials.gov/ct2/show/NCT04368988) - 1,419 subjects (US, Australia) - Started May 25 2020 - [Results](https://www.medrxiv.org/content/10.1101/2020.08.05.20168435v1)
- [Phase 2b](https://clinicaltrials.gov/ct2/show/NCT04533399) - 4,422 subjects (South Africa) - Started August 17, 2020
- [Phase 3](https://www.clinicaltrials.gov/ct2/show/NCT04583995) - 15,000 subjects (UK) - started September 28, 2020
- [Phase 3](https://www.clinicaltrials.gov/ct2/show/NCT04611802) - 30,000 subjects - Started December 27 2020

**Medicago** - CoVLP
- [Phase 1](https://www.clinicaltrials.gov/ct2/show/NCT04450004) - 180 subjects - Started July 10, 2020
- [Phase 2/3](https://www.clinicaltrials.gov/ct2/show/NCT04636697) - 30,918 subjects - Started November 19 2020

**Bharat Biotech** - BBV152
- [Phase 1/2](http://ctri.nic.in/Clinicaltrials/showallp.php?mid1=45184&amp;EncHid=&amp;userName=bbv152) - 1,125 subjects (India) - Started July 13 2020 - [P1 Results](https://www.clinicaltrialsarena.com/news/bharat-biotech-covaxin-data/)
- [Phase 1/2](https://clinicaltrials.gov/ct2/show/NCT04471519?term=BBV152&amp;draw=2&amp;rank=1) - 755 - Started July 13 2020
- [Phase 3](http://ctri.nic.in/Clinicaltrials/showallp.php?mid1=48057&amp;EncHid=&amp;userName=CTRI/2020/11/028976) - 25,800 - Started November 11 2020

**Bektop** - EpiVacCorona
- [Phase 1/2](https://clinicaltrials.gov/ct2/show/NCT04527575) - 100 subjects - July 27 2020
- [Phase 3](https://www.interfax.ru/russia/741335) - 1,438 subjects - Started November 2020

**CureVac** - CVnCoV
- [Phase 1](https://www.clinicaltrials.gov/ct2/show/NCT04449276) - 280 subjects - Started June 18 2020
- [Phase 2](https://www.clinicaltrials.gov/ct2/show/NCT04515147) - 674 subjects - Started September 28 2020
- [Phase 3](https://www.clinicaltrials.gov/ct2/show/NCT04652102) - 36,500 subjects - Started November 30 2020
- [Phase 3](https://clinicaltrials.gov/ct2/show/NCT04674189) - 2,520 subjects - Started December 23 2020

**Anhui Zhifei** - Recombinant Coronavirus Vaccine
- [Phase 1](https://clinicaltrials.gov/ct2/show/NCT04445194) - 50 subjects (China) - Started June 22 2020
- [Phase 2](https://clinicaltrials.gov/ct2/show/NCT04466085) - 900 subjects (China) - Started July 12 2020
- [Phase 1/2](https://clinicaltrials.gov/ct2/show/NCT04550351) - 50 subjects (China) - Started August 19 2020
- [Phase 1](https://clinicaltrials.gov/ct2/show/NCT04636333) - 216 subjects (China) - Started October 30 2020
- [Phase 3](https://clinicaltrials.gov/ct2/show/NCT04646590) - 29,000 subjects (China) - Started December 16 2020
- [Phase 3](http://www.xinhuanet.com/english/2021-02/01/c_139713602.htm) - 9,000 subjects (Uzbekistan) - Started [December 11](https://medicalxpress.com/news/2020-12-uzbekistan-phase-trials-chinese-vaccine.html) 2020

**RIBSP** - QazCovid
- [Phase 1/2](https://clinicaltrials.gov/ct2/show/NCT04530357) - 244 subjects (Kazakhstan) - Started September 19 2020
- [Phase 3](https://clinicaltrials.gov/ct2/show/NCT04691908) - 3,000 subjects (Kazakhstan) - Started December 25 2020

**Zydus Cadilla** - DNA plasmid Vaccine
- [Phase 1/2](http://ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=45306&amp;EncHid=&amp;userName=vaccine) - 1,048 subjects (India) - Started July 15 2020
- [Phase 3](http://ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=51254&amp;EncHid=&amp;userName=ZyCoV-D) - 28,216 subjects - Started 20 January 2021

**Chinese Academy of Medical Sciences** - Inactivated SARS-CoV-2 Vaccine
- [Phase 1/2](https://clinicaltrials.gov/ct2/show/NCT04412538) - 942 subjects (China) - Started May 15 2020
- [Phase 1/2](https://clinicaltrials.gov/ct2/show/NCT04470609) - 471 subjects (China) - Started July 10 2020
- [Phase 3](https://clinicaltrials.gov/ct2/show/NCT04659239) - 34,020 subjects (Brazil, Malaysia) - Started January 28 2021

**Inovio** - INO-4800
- [Phase 1](https://clinicaltrials.gov/ct2/show/NCT04336410) - 120 subjects (US) - Started April 3 2020 - [Interim Results](https://www.statnews.com/2020/06/30/inovio-claims-positive-results-on-covid-19-vaccine-but-critical-data-are-missing/)
- [Phase 1/2](https://clinicaltrials.gov/ct2/show/NCT04447781) - 160 subjects (US) - Started July 15 2020
- [Phase 2/3](https://www.clinicaltrials.gov/ct2/show/NCT04642638?term=inovio&amp;draw=2&amp;rank=1) - 6,578 subjects (US) - Started November 30 2020
Phase 3 - Starting 2Q21

**AnGes** - AG0302-COVID19
- [Phase 1/2](https://www.clinicaltrials.gov/ct2/show/NCT04527081) - 30 subjects (Japan) - Started August 31 2020
- [Phase 2/3](https://clinicaltrials.gov/ct2/show/NCT04655625) - 500 subjects (Japan) - Started November 23 2020

---
**Note** : Includes vaccines that have reached Phase 3. Trial Registry links and publication linked provided if available, otherwise news articles linked.

**Other Sources of Information** :

[STAT News](https://www.statnews.com/feature/coronavirus/drugs-vaccines-tracker/?utm_campaign=cv_landing#vaccines)

[Clinical Trials Arena](https://www.clinicaltrialsarena.com/tag/coronavirus/)

[TrialSiteNews](https://www.trialsitenews.com/the-covid-19-vaccine-race-status-update-as-of-july-5-2020/)

[Milken Tracker](https://covid-19tracker.milkeninstitute.org/#vaccines_intro)

[NYT Vaccine Tracker](https://www.nytimes.com/interactive/2020/science/coronavirus-vaccine-tracker.html)

[WHO Draft Landscape](https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines)

[McGill Vaccine Tracker](https://covid19.trackvaccines.org/vaccines/)

[RA Capital Tracker](https://www.racap.com/covid-19)

[BioWorld Tracker](https://www.bioworld.com/COVID19products)

[Coronavirus Today](https://www.coronavirustoday.com/coronavirus-vaccines-0)
